## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Thermo Fisher Scientific (TMO) SVP & General Counsel reports Form 4 stock sale**
- Source: Stock Titan | 20251203T215000 | Neutral | Relevance: 100%
- Thermo Fisher Scientific's SVP and General Counsel, Thomas B. Shropshire, Jr., reported the sale of 337.476 shares of company common stock on December 2, 2025, at a price of $580.37 per share. This transaction, filed as an SEC Form 4, resulted in him beneficially owning 5,079.524 shares directly afterward. The filing indicates a "Neutral" impact and "Negative" sentiment regarding the insider transaction.

**2. TMO Stock Benefits From New Bioprocess Design Center in Asia**
- Source: TradingView | 20251203T200635 | Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) recently expanded its bioprocessing capabilities in Asia by opening a new Bioprocess Design Center in Hyderabad, India, and expanding existing centers in South Korea and Singapore. This strategic move aims to enhance speed, efficiency, and sustainability in biomanufacturing in the rapidly growing Asian biopharmaceutical market. The expansion is expected to boost market sentiment for TMO stock, which already shows strong earnings and revenue growth forecasts.

**3. Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts**
- Source: ts2.tech | 20251202T185537 | Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) is experiencing significant activity on December 2, 2025, including a stock price near its 52-week high, a new €2.1 billion bond deal, a $5 billion share repurchase authorization, and an HSBC price target upgrade to $670. The company's strong Q3 2025 earnings, strategic acquisitions like Clario, and partnerships with OpenAI for AI integration are driving positive analyst sentiment, though valuation risks and mixed algorithmic forecasts suggest varying long-term outlooks.

**4. Thermo Fisher (TMO) boosts Asia biopharma support with new and expanded design centers**
- Source: Stock Titan | 20251202T170000 | Bullish | Relevance: 100%
- Thermo Fisher Scientific announced the expansion of its bioprocessing capabilities in Asia with a new Bioprocess Design Center in Hyderabad, India, and expanded centers in Incheon, Korea, and Singapore. These strategic investments aim to support the rapidly growing biopharmaceutical industry in Asia by providing local expertise, advanced technologies, and tailored support for biopharma innovators. The expanded network will accelerate process development and help customers deliver high-quality biologics faster and more sustainably.

**5. HSBC Upgrades Thermo Fisher Scientific to Buy From Hold, Adjusts Price Target to $670 From $550**
- Source: MarketScreener | 20251201T052100 | Bullish | Relevance: 100%
- HSBC has upgraded Thermo Fisher Scientific's rating from Hold to Buy and increased its price target to $670 from $550. This positive analyst action reflects a more optimistic outlook for the company's stock performance. The article also provides recent news on insider transactions, note offerings, FDA approvals for diagnostic tests, and a significant share repurchase program.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.3M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.2B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.5 |
| Current P/E | 25.5 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.3% to -1.9% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-2.01), momentum weakening. RSI neutral at 56. OFD pattern: -DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.86% (CS: 32) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | -2.01 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.051x | Above |
| vs SMA200 | 1.208x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $580.45
- **Stop Loss:** $554.89 (4.4% risk)
- **Target:** $606.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 37
- **Position Value:** $21,476.65
- **Portfolio %:** 21.48%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*